7CN2

Subparticle refinement of human papillomavirus type 16 pesudovirus in complex with H16.001 Fab

Summary for 7CN2

• Entry DOI: 10.2210/pdb7cn2/pdb
• EMDB information: 30414
• Descriptor: The light chain variable region of H16.001 Fab fragment, The heavy chain variable region of H16.001 Fab fragment, Major capsid protein L1 (3 entities in total)
• Functional Keywords: virus, immune complex, immune system-viral protein complex, immune system/viral protein
• Biological source: Human papillomavirus type 16; More
• Total number of polymer chains: 18
• Total formula weight: 486381.04

Authors

He, M.Z.,Li, S.W. (deposition date: 2020-07-29, release date: 2020-09-02, Last modification date: 2024-10-23)

Primary citation

Huang, W.,He, M.,Ning, T.,Nie, J.,Zhang, F.,Zheng, Q.,Zhang, R.,Xu, Y.,Gu, Y.,Li, S.,Wang, Y.
Structural characterization of a neutralizing mAb H16.001, a potent candidate for a common potency assay for various HPV16 VLPs.
Npj Vaccines, 5:89-89, 2020

PubMed Abstract: With more human papillomavirus (HPV) virus-like particle (VLP) vaccines to hit the market in future, a monoclonal antibody (mAb) with preferably comparable reactivity against vaccines from different expression systems and bioprocesses is urgently needed for the potency characterization. Among all mAbs against HPV16 collected, rabbit mAb H16.001 is potently neutralizing with the highest affinity, recognizes an immune-dominant epitope, and can comparably react with HPV16 vaccines from various sources. Cryo-electron microscopic (cryo-EM) structure demonstrated that 360 H16.001 Fabs could bind to HPV16 capsid in preferable binding manner without steric hindrance between neighboring Fabs, potentially supporting its identification for VLP structural integrity and utility in monitoring VLP structural probity. This structural analysis indicated that mAb H16.001 afforded unbiased potency characterization for various HPV16 vaccines and was potential for use in vaccine regulation practice. This study also showed a model process for selecting suitable mAbs for potency assays of other vaccines.

PubMed: 33042588
DOI: 10.1038/s41541-020-00236-w

Experimental method

ELECTRON MICROSCOPY (3.43 Å)